Found: 2
Select item for more details and to access through your institution.
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain.
- Published in:
- Pediatric Allergy & Immunology, 2023, v. 34, n. 4, p. 1, doi. 10.1111/pai.13942
- By:
- Publication type:
- Article
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
- Published in:
- Pediatric Allergy & Immunology, 2021, v. 32, n. 5, p. 980, doi. 10.1111/pai.13484
- By:
- Publication type:
- Article